# Cyngn Inc.: financial statements, quarterly

CYN · Nasdaq · CIK 1874097 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cyn.md) · [Financials](/companies/cyn/financials.md) · [Filings](/companies/cyn/filings.md) · [Insiders](/companies/cyn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cyn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001213900-24-095459.md) | [0.0 d](/filings/0001213900-25-110998.md) | [0.0](/filings/0001213900-25-041094.md) | [0.0](/filings/0001213900-25-073134.md) | [0.0](/filings/0001213900-25-112611.md) | [0.3 d](/filings/0001213900-26-034900.md) | [0.0](/filings/0001213900-26-056821.md) | [0.0](/filings/0001437749-26-027718.md) | [0.1](/filings/0001213900-25-112611.md) | [0.1 d](/filings/0001213900-26-034900.md) | [0.1](/filings/0001213900-26-056821.md) | [0.1](/filings/0001437749-26-027718.md) |
| Cost of revenue | $m | [0.0](/filings/0001213900-24-095459.md) | [0.1 d](/filings/0001213900-25-110998.md) | [0.1](/filings/0001213900-25-041094.md) | [0.0](/filings/0001213900-25-073134.md) | [0.2](/filings/0001213900-25-112611.md) | [0.2 d](/filings/0001213900-26-034900.md) | [0.0](/filings/0001213900-26-056821.md) | [0.0](/filings/0001213900-25-073134.md) | [0.1](/filings/0001213900-25-112611.md) | [0.1 d](/filings/0001213900-26-034900.md) | [0.1](/filings/0001213900-26-056821.md) | [0.1](/filings/0001437749-26-027718.md) |
| Research and development | $m | [2.9](/filings/0001213900-24-095459.md) | [3.0 d](/filings/0001213900-25-110998.md) | [3.2](/filings/0001213900-25-041094.md) | [3.2](/filings/0001213900-25-073134.md) | [2.8](/filings/0001213900-25-112611.md) | [2.1 d](/filings/0001213900-26-034900.md) | [2.1](/filings/0001213900-26-056821.md) | [2.0](/filings/0001437749-26-027718.md) | [5.3](/filings/0001213900-25-112611.md) | [3.1 d](/filings/0001213900-26-034900.md) | [2.9](/filings/0001213900-26-056821.md) | [3.2](/filings/0001437749-26-027718.md) |
| Operating income | $m | [(5.6)](/filings/0001213900-24-095459.md) | [(5.4) d](/filings/0001213900-25-110998.md) | [(6.0)](/filings/0001213900-25-041094.md) | [(5.8)](/filings/0001213900-25-073134.md) | [(5.5)](/filings/0001213900-25-112611.md) | [(5.5) d](/filings/0001213900-26-034900.md) | [(5.2)](/filings/0001213900-26-056821.md) | [(5.5)](/filings/0001437749-26-027718.md) | [(8.4)](/filings/0001213900-25-112611.md) | [(6.6) d](/filings/0001213900-26-034900.md) | [(6.9)](/filings/0001213900-26-056821.md) | [(6.8)](/filings/0001437749-26-027718.md) |
| Income tax | $m | [0.0](/filings/0001213900-24-095459.md) | not reported | [0.0](/filings/0001213900-25-041094.md) | [0.0](/filings/0001213900-25-073134.md) | [0.0](/filings/0001213900-25-112611.md) | not reported | [0.0](/filings/0001213900-25-041094.md) | [0.0](/filings/0001437749-26-027718.md) | [0.0](/filings/0001213900-25-112611.md) | not reported | not reported | [0.0](/filings/0001437749-26-027718.md) |
| Net income | $m | [(5.5)](/filings/0001213900-24-095459.md) | [(5.4) d](/filings/0001213900-25-110998.md) | [(6.0)](/filings/0001213900-25-041094.md) | [(5.8)](/filings/0001213900-25-073134.md) | [(5.4)](/filings/0001213900-25-112611.md) | [(16.1) d](/filings/0001213900-26-034900.md) | [(3.9)](/filings/0001213900-26-056821.md) | [(5.4)](/filings/0001437749-26-027718.md) | [(8.4)](/filings/0001213900-25-112611.md) | [(5.7) d](/filings/0001213900-26-034900.md) | [(6.5)](/filings/0001213900-26-056821.md) | [(6.4)](/filings/0001437749-26-027718.md) |
| Diluted EPS | $ per share | [(11.03)](/filings/0001213900-24-095459.md) | not reported | [(422.87)](/filings/0001213900-25-041094.md) | [(610.85)](/filings/0001213900-25-073134.md) | [(408.30)](/filings/0001213900-25-112611.md) | not reported | [(3.40)](/filings/0001213900-26-056821.md) | [(2.70)](/filings/0001213900-25-073134.md) | [(1.20)](/filings/0001213900-25-112611.md) | not reported | [(0.59)](/filings/0001213900-26-056821.md) | not reported |
| Basic EPS | $ per share | [(11.03)](/filings/0001213900-24-095459.md) | not reported | [(422.87)](/filings/0001213900-25-041094.md) | [(610.85)](/filings/0001213900-25-073134.md) | [(408.30)](/filings/0001213900-25-112611.md) | not reported | [(3.40)](/filings/0001213900-26-056821.md) | [(2.70)](/filings/0001437749-26-027718.md) | [(1.20)](/filings/0001213900-25-112611.md) | not reported | [(0.59)](/filings/0001213900-26-056821.md) | [(0.45)](/filings/0001437749-26-027718.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.5](/filings/0001213900-23-084879.md) | [3.6](/filings/0001213900-24-066682.md) | [2.2](/filings/0001213900-24-041350.md) | [5.9](/filings/0001213900-24-066682.md) | [2.0](/filings/0001213900-24-095459.md) | [23.6](/filings/0001213900-26-034900.md) | [1.0](/filings/0001213900-25-041094.md) | [31.3](/filings/0001213900-25-073134.md) | [4.8](/filings/0001213900-25-112611.md) | [1.0](/filings/0001437749-26-027718.md) | [5.1](/filings/0001213900-26-056821.md) | [2.2](/filings/0001437749-26-027718.md) |
| Current assets | $m | [8.6](/filings/0001213900-23-084879.md) | [9.5](/filings/0001213900-25-110998.md) | [6.3](/filings/0001213900-24-041350.md) | [8.3](/filings/0001213900-24-066682.md) | [4.5](/filings/0001213900-24-095459.md) | [25.6](/filings/0001213900-26-034900.md) | [18.7](/filings/0001213900-25-041094.md) | [43.6](/filings/0001213900-25-073134.md) | [39.1](/filings/0001213900-25-112611.md) | [39.2](/filings/0001437749-26-027718.md) | [49.9](/filings/0001213900-26-056821.md) | [44.0](/filings/0001437749-26-027718.md) |
| Total assets | $m | [11.6](/filings/0001213900-23-084879.md) | [13.0](/filings/0001213900-25-110998.md) | [9.8](/filings/0001213900-24-041350.md) | [11.9](/filings/0001213900-24-066682.md) | [8.5](/filings/0001213900-24-095459.md) | [30.1](/filings/0001213900-26-034900.md) | [24.3](/filings/0001213900-25-041094.md) | [56.2](/filings/0001213900-25-073134.md) | [49.3](/filings/0001213900-25-112611.md) | [50.1](/filings/0001437749-26-027718.md) | [61.0](/filings/0001213900-26-056821.md) | [55.0](/filings/0001437749-26-027718.md) |
| Current liabilities | $m | not reported | [2.1](/filings/0001213900-25-110998.md) | [1.7](/filings/0001213900-24-041350.md) | [2.2](/filings/0001213900-24-066682.md) | [1.8](/filings/0001213900-24-095459.md) | [3.4](/filings/0001213900-26-034900.md) | [2.2](/filings/0001213900-25-041094.md) | [3.0](/filings/0001213900-25-073134.md) | [3.9](/filings/0001213900-25-112611.md) | [3.5](/filings/0001437749-26-027718.md) | [4.1](/filings/0001213900-26-056821.md) | [2.7](/filings/0001437749-26-027718.md) |
| Total liabilities | $m | [1.3](/filings/0001213900-23-084879.md) | [2.4](/filings/0001213900-25-110998.md) | [1.8](/filings/0001213900-24-041350.md) | [2.2](/filings/0001213900-24-066682.md) | [1.8](/filings/0001213900-24-095459.md) | [31.1](/filings/0001213900-26-034900.md) | [2.2](/filings/0001213900-25-041094.md) | [9.4](/filings/0001213900-25-073134.md) | [10.6](/filings/0001213900-25-112611.md) | [11.3](/filings/0001437749-26-027718.md) | [10.4](/filings/0001213900-26-056821.md) | [10.4](/filings/0001437749-26-027718.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [10.2](/filings/0001213900-24-095459.md) | [10.6](/filings/0001213900-26-034900.md) | [8.0](/filings/0001213900-25-073134.md) | [9.7](/filings/0001213900-25-112611.md) | [6.6](/filings/0001213900-25-112611.md) | [(1.0)](/filings/0001437749-26-027718.md) | [22.1](/filings/0001437749-26-027718.md) | [46.8](/filings/0001437749-26-027718.md) | [38.7](/filings/0001213900-25-112611.md) | [38.8](/filings/0001437749-26-027718.md) | [50.6](/filings/0001437749-26-027718.md) | [44.6](/filings/0001437749-26-027718.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,193) d](/filings/0001213900-24-095459.md) | [(5,038) d](/filings/0001213900-25-110998.md) | [(5,840)](/filings/0001213900-25-041094.md) | [(4,385) d](/filings/0001213900-25-073134.md) | [(5,325) d](/filings/0001213900-25-112611.md) | [(3,646) d](/filings/0001213900-26-034900.md) | [(6,513)](/filings/0001213900-26-056821.md) | [(6,257) d](/filings/0001437749-26-027718.md) | [(4,065) d](/filings/0001213900-25-112611.md) | [(6,741) d](/filings/0001213900-26-034900.md) | [(8,404)](/filings/0001213900-26-056821.md) | [(4,754) d](/filings/0001437749-26-027718.md) |
| Capital expenditure | $k | [423 d](/filings/0001213900-24-095459.md) | [141 d](/filings/0001213900-25-110998.md) | [214](/filings/0001213900-25-041094.md) | [363 d](/filings/0001213900-25-073134.md) | [162 d](/filings/0001213900-25-112611.md) | [312 d](/filings/0001213900-26-034900.md) | [178](/filings/0001213900-26-056821.md) | [174 d](/filings/0001437749-26-027718.md) | [520 d](/filings/0001213900-25-112611.md) | [358 d](/filings/0001213900-26-034900.md) | [289](/filings/0001213900-26-056821.md) | [326 d](/filings/0001437749-26-027718.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.7](/filings/0001213900-23-065594.md) | [37.0](/filings/0001213900-23-084879.md) | [37.7](/filings/0001213900-24-041350.md) | [0.5](/filings/0001213900-24-066682.md) | [0.5](/filings/0001213900-24-095459.md) | [0.0](/filings/0001213900-25-041094.md) | [0.0](/filings/0001213900-25-073134.md) | [0.0](/filings/0001213900-25-112611.md) | [1.2](/filings/0001213900-26-056821.md) | [2.0](/filings/0001213900-25-073134.md) | [7.0](/filings/0001213900-25-112611.md) | [11.0](/filings/0001213900-26-056821.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,423,281 at 2026-08-13, from the cover of the [10-Q/A filed 2026-08-14](/filings/0001213900-26-089408.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.